MEI Pharma Inc  

(Public, NASDAQ:MEIP)   Watch this stock  
Find more results for MEIP
-0.02 (-1.16%)
Oct 8 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.68 - 1.74
52 week 1.47 - 8.33
Open 1.70
Vol / Avg. 224,821.00/341,869.00
Mkt cap 58.75M
P/E     -
Div/yield     -
EPS -1.23
Shares 34.16M
Beta 0.51
Inst. own 31%
Sep 2, 2015
Full Year 2015 MEI Pharma Inc Earnings Release
Aug 11, 2015
MEI Pharma Inc at Wedbush PacGrow Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.31% -57.08%
Return on average equity -36.41% -62.28%
Employees 20 -
CDP Score - -


Suite 101, 11975 El Camino Real
United States - Map
+1-858-7926300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Officers and directors

Daniel P. Gold Ph.D. President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Christine Anna White M.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Charles V. Baltic III Independent Director
Age: 53
Bio & Compensation  - Reuters
Leah Rush Cann Independent Director
Age: 54
Bio & Compensation  - Reuters
Kevan E. Clemens Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Thomas C. Reynolds M.D., Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters